183 related articles for article (PubMed ID: 33948902)
1. Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice.
Lin R; Ma B; Liu N; Zhang L; He T; Liu X; Chen T; Liu W; Liang Y; Wang T; Ni G; Liu X; Yang N; Zhang J; Yuan J
Ann Nucl Med; 2021 Jul; 35(7):811-822. PubMed ID: 33948902
[TBL] [Abstract][Full Text] [Related]
2. Iodine-125 labeled Australian frog tree host-defense peptides caerin 1.1 and 1.9 better inhibit human breast cancer cells growth than the unlabeled peptides.
Yuan J; You X; Ni G; Wang T; Cavezza S; Pan X; Liu X
Hell J Nucl Med; 2018; 21(2):115-120. PubMed ID: 30006645
[TBL] [Abstract][Full Text] [Related]
3. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
4. Investigating the theragnostic potential of
Zhou YY; Zhang PP; Lin RT; Chen TS; Liu XY; Liu WJ; Liang YN; Chen S; Pan X; Ni GY; Wang TF; Liu XS; Yuan JW
Hell J Nucl Med; 2020; 23(1):27-33. PubMed ID: 32222729
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Saï-Maurel C; Campion L; Faivre-Chauvet A; Mirallié E; Chérel M; Supiot S; Barbet J; Chatal JF; Thédrez P
Mol Cancer Ther; 2002 Feb; 1(4):267-74. PubMed ID: 12467222
[TBL] [Abstract][Full Text] [Related]
6. Experimental study of
He T; Du J; Zhu K; Zhou Y; Xiao Z; Liu W; Ren W; Liu X; Chen T; Liu W; Chen Z; Ni G; Liu X; Wang T; Quan J; Zhang P; Yuan J
Biomed Pharmacother; 2023 Aug; 164():114891. PubMed ID: 37209630
[TBL] [Abstract][Full Text] [Related]
7.
Liu N; He T; Xiao Z; Du J; Zhu K; Liu X; Chen T; Liu W; Ni G; Liu X; Wang T; Quan J; Zhang J; Zhang P; Yuan J
Front Oncol; 2022; 12():861206. PubMed ID: 36046040
[TBL] [Abstract][Full Text] [Related]
8. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
9. Lipid-Peptide-mRNA Nanoparticles Augment Radioiodine Uptake in Anaplastic Thyroid Cancer.
Li Q; Zhang L; Lang J; Tan Z; Feng Q; Zhu F; Liu G; Ying Z; Yu X; Feng H; Yi H; Wen Q; Jin T; Cheng K; Zhao X; Ge M
Adv Sci (Weinh); 2023 Jan; 10(3):e2204334. PubMed ID: 36453580
[TBL] [Abstract][Full Text] [Related]
10. MEK Inhibition Induces Therapeutic Iodine Uptake in a Murine Model of Anaplastic Thyroid Cancer.
ElMokh O; Taelman V; Radojewski P; Roelli MA; Stoss A; Dumont RA; Dettmer MS; Phillips WA; Walter MA; Charles RP
J Nucl Med; 2019 Jul; 60(7):917-923. PubMed ID: 30464041
[TBL] [Abstract][Full Text] [Related]
11. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
[No Abstract] [Full Text] [Related]
12. Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2.
Wang C; Zhang R; Tan J; Meng Z; Zhang Y; Li N; Wang H; Chang J; Wang R
Oncol Rep; 2020 May; 43(5):1491-1502. PubMed ID: 32323855
[TBL] [Abstract][Full Text] [Related]
13. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
14. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
Zhu X; Park S; Lee WK; Cheng SY
Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
[TBL] [Abstract][Full Text] [Related]
15. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten.
Gautherot E; Bouhou J; Le Doussal JM; Manetti C; Martin M; Rouvier E; Barbet J
Cancer; 1997 Dec; 80(12 Suppl):2618-23. PubMed ID: 9406716
[TBL] [Abstract][Full Text] [Related]
16. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
[TBL] [Abstract][Full Text] [Related]
17. Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer.
Zhou M; Chen Y; Adachi M; Wen X; Erwin B; Mawlawi O; Lai SY; Li C
Biomaterials; 2015 Jul; 57():41-9. PubMed ID: 25913249
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.
Salaun PY; Bodet-Milin C; Frampas E; Oudoux A; Saï-Maurel C; Faivre-Chauvet A; Barbet J; Paris F; Kraeber-Bodéré F
Cancer; 2010 Feb; 116(4 Suppl):1053-8. PubMed ID: 20127950
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and characterization of CD133 targeted aptamer-drug conjugates for precision therapy of anaplastic thyroid cancer.
Ge MH; Zhu XH; Shao YM; Wang C; Huang P; Wang Y; Jiang Y; Maimaitiyiming Y; Chen E; Yang C; Naranmandura H
Biomater Sci; 2021 Feb; 9(4):1313-1324. PubMed ID: 33350399
[TBL] [Abstract][Full Text] [Related]
20. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Bodet-Milin C; Niaudet C; Saï-Maurel C; Moreau A; Faivre-Chauvet A; Thomare P; Deleris G; Estieu-Gionnet K; Bikfalvi A; Barbet J; Paris F
J Nucl Med; 2010 Apr; 51(4):624-31. PubMed ID: 20351352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
